BioCryst

YTD

ALL

Trade BioCryst 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BCRX

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases.

CEO

Charles K. Gayer

CEOCharles K. Gayer

Employees

435

Employees435

Headquarters

Durham, North Carolina

HeadquartersDurham, North Carolina

Founded

1986

Founded1986

Employees

435

Employees435

BCRX Key Statistics

Market cap

2.32B

Market cap2.32B

Price-Earnings ratio

-5.13

Price-Earnings ratio-5.13

Dividend yield

—

Dividend yield—

Average volume

4.82M

Average volume4.82M

High today

—

High today—

Low today

—

Low today—

Open price

$9.37

Open price$9.37

Volume

0.00

Volume0.00

52 Week high

$11.22

52 Week high$11.22

52 Week low

$6.00

52 Week low$6.00

Stock Snapshot

BioCryst(BCRX) stock is priced at $9.11, giving the company a market capitalization of 2.32B. It carries a P/E multiple of -5.13.

On 2026-07-21, BioCryst(BCRX) stock opened at $9.37, reached a high of —, and a low of —.

BioCryst(BCRX) shares are trading with a volume of 0, against a daily average of 4.82M.

During the past year, BioCryst(BCRX) stock moved between $6.00 at its lowest and $11.22 at its peak.

BCRX News

Simply Wall St 23h

Can BioCryst Pharmaceuticals Be Worth More As A New CSO Sharpens Its Pipeline Story?

BioCryst Pharmaceuticals (BCRX) has created a new Chief Scientific Officer role and appointed David W. Jenkins, an industry veteran with broad R&D and external...

TipRanks 6d

BioCryst appoints David Jenkins as chief scientific officer

BioCryst (BCRX) announced the appointment of David Jenkins to the newly created position of chief scientific officer, effective immediately, reporting to Sandee...

Simply Wall St 6d

BioCryst Stock Looks Like A Bargain After Facility Closure

BioCryst Pharmaceuticals stock has rebounded in recent years but is still down about 40.0% over five years, which sits alongside valuation checks that currently...

Analyst ratings

91%

of 11 ratings

Buy

90.9%

Hold

9.1%

Sell

More BCRX News

Nasdaq 7d

Wall Street Analysts Think BioCryst Could Surge 117.96%: Read This Before Placing a Bet

Shares of BioCryst Pharmaceuticals (BCRX) have gained 9.4% over the past four weeks to close the last trading session at $9.91, but there could still be a solid...

People also own

Based on the portfolios of people who own BCRX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.